Holen Sie sich die Stockscreener-App
1.57
1.62%
0.025
Schlusskurs vom Vortag:
$1.545
Offen:
$1.58
24-Stunden-Volumen:
15,491
Relative Volume:
0.31
Marktkapitalisierung:
$26.58M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.36M
KGV:
-0.0323
EPS:
-48.648
Netto-Cashflow:
$-21.40M
1W Leistung:
-7.10%
1M Leistung:
-21.89%
6M Leistung:
-81.74%
1J Leistung:
-85.16%
1-Tages-Spanne:
$1.545
$1.66
1-Wochen-Bereich:
$1.52
$1.81
52-Wochen-Spanne:
$1.52
$20.99
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Firmenname
Transcode Therapeutics Inc
Sektor
Branche
Telefon
857-301-6857
Adresse
6 LIBERTY SQUARE, BOSTON
Compare RNAZ vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
1.57 | 28.61M | 0 | -40.36M | -21.40M | -48.65 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Transcode Therapeutics Inc Aktie (RNAZ) Neueste Nachrichten
TransCode Therapeutics Eases Near-Term Obligations Under Financing - TipRanks
Form 8K Transcode Therapeutics Inc For: 1 October - Investing.com India
TransCode Therapeutics makes $840,975 prepayment under convertible notes agreement - Investing.com India
TransCode’s TTX-MC138 Shows 71.4% Stable Disease Rate in Phase 1a Trial - Minichart
TransCode Highlights Promising Phase 1a Results for TTX-MC138 - TipRanks
TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up - PR Newswire
TransCode Therapeutics, Inc. (RNAZ) Stock Price, News, Quote & History - Yahoo! Finance Canada
TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology - PR Newswire
A cancer treatment technology gains a Japan patent. Australia may follow. - Stock Titan
Transcode Therapeutics (RNAZ) interim CFO becomes reporting insider with no listed stake - Stock Titan
Transcode Therapeutics Inc (NASDAQ: RNAZ) Share Price, RNAZ Stock News, RNAZ Share Price & Updates - kalkine.com.au
Join Today's Live Investor Webinar with TransCode Therapeutics - ACCESS Newswire
Fitzgerald Thomas A Granted 185,000 Derivative Securities in Transcode Therapeutics on September 9, 2026 - Kalkine Media
TransCode Therapeutics Share PriceRNAZ, RNS News, Articles, Quotes, & Charts (NASDAQ:RNAZ) - Proactive financial news
TransCode Therapeutics CFO Resigns, Interim Replacement Named - minichart.com.sg
Form 8K Transcode Therapeutics Inc For: 11 September By Investing.com - Investing.com Nigeria
Transcode Therapeutics announces CFO resignation and interim appointment - Investing.com
TransCode Therapeutics Announces CFO Resignation and Interim Appointment - TipRanks
Transcode Therapeutics (RNAZ) grants CFO 185,000 options with 10-year term - Stock Titan
CFO exit at TransCode Therapeutics (RNAZ) comes with severance tied to future funding - Stock Titan
TransCode Therapeutics Appoints Interim CFO Following Retirement of Tom Fitzgerald - citybuzz -
TransCode Therapeutics Appoints John Tattory As Interim CFO - TradingView
Transcode Therapeutics, Inc. Announces Management Changes, Effective from September 9, 2026 - marketscreener.com
TransCode Therapeutics CFO Tom Fitzgerald retires; John Tattory named interim CFO - Pluang
Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer - Yahoo Finance
An RNA-based treatment showed a survival benefit in mice with breast cancer spread to bone - Stock Titan
RNAZ Q4 2024 Earnings: Significant EPS Miss as Clinical-Stage Biotech Reports No RevenueEarnings Seasonality - dars.gov.et
TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-than-Expected Loss of $150.64 Per Share Weighs on SharesEarnings Yield Spread - vinanet.vn
TransCode Therapeutics (NASDAQ: RNAZ) logs $24.5M loss and funding strain - Stock Titan
TransCode Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
TransCode Therapeutics (RNAZ) Holds Above $3.50 as Shares Grind Higher in Quiet SessionExhaustion Gap - vinanet.vn
TransCode Therapeutics (RNAZ) Advances 3.26% to $3.48, Approaching Key Resistance at $3.65Sector Neutral Pair - vinanet.vn
Transcode Therapeutics Inc (RNAZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Transcode Therapeutics Inc (RNAZ) Stock News Today - TradingKey
Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - ACCESS Newswire
Why (RNAZ) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Major holder converts preferred shares at Transcode Therapeutics, Inc. (RNAZ) - stocktitan.net
Transcode Therapeutics (RNAZ) major holders disclose convertible preferred stake - Stock Titan
TransCode Therapeutics Updates Preferred Stock Governance Terms - The Globe and Mail
DEFJ lifts TransCode Therapeutics (RNAZ) stake to 83.9% after conversions - Stock Titan
TransCode Therapeutics (RNAZ) Retreats 2.7% to $4.62, Approaching Key Support ZoneDiamond Pattern - dars.gov.et
TransCode Therapeutics Q4 2024 Earnings: Wider-than-Expected Loss of -$150.64 Per Share Signals Ongoing Clinical-Stage Cash BurnFinancial Health Score - siam.in
RNAZ|Transcode Therapeutics Inc|Price:5.800|Chg%:-0.130 - TradingKey
Unleash Immuno Oncolytics (RNAZ holder) reports 9.94% TransCode Therapeutics stake - Stock Titan
Transcode Therapeutics Inc (RNAZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TransCode Therapeutics (RNAZ) holder moves toward controlling stake via conversions - Stock Titan
Transcode Therapeutics Inc (RNAZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RNAZ|Transcode Therapeutics Inc|Price:5.930|Chg%:-1.170 - TradingKey
Transcode Therapeutics Inc (RNAZ) Balance Sheet - TradingKey
TransCode Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNAZ - TradingView
RNAZ|Transcode Therapeutics Inc|Price:3.995|Chg%:+0.035 - TradingKey
Finanzdaten der Transcode Therapeutics Inc-Aktie (RNAZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):